These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19115972)

  • 61. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions.
    Kapoor S
    AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242
    [No Abstract]   [Full Text] [Related]  

  • 64. Human leukocyte antigens and drug hypersensitivity.
    Chung WH; Hung SI; Chen YT
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.
    Sanchez-Giron F; Villegas-Torres B; Jaramillo-Villafuerte K; Silva-Zolezzi I; Fernandez-Lopez JC; Jimenez-Sanchez G; Carnevale A
    Pharmacogenomics; 2011 Jun; 12(6):809-14. PubMed ID: 21510768
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.
    Siljic M; Salemovic D; Cirkovic V; Pesic-Pavlovic I; Todorovic M; Ranin J; Dragovic G; Jevtovic D; Stanojevic M
    Intervirology; 2017; 60(1-2):43-47. PubMed ID: 28772259
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Abacavir hypersensitivity.
    Abel S; Paturel L; Cabié A
    N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095
    [No Abstract]   [Full Text] [Related]  

  • 68. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
    Sousa-Pinto B; Pinto-Ramos J; Correia C; Gonçalves-Costa G; Gomes L; Gil-Mata S; Araújo L; Delgado L
    J Allergy Clin Immunol; 2015 Oct; 136(4):1092-4.e3. PubMed ID: 25934581
    [No Abstract]   [Full Text] [Related]  

  • 69. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 72. External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription.
    Darke C; Corbin SA
    Int J Immunogenet; 2014 Aug; 41(4):277-80. PubMed ID: 24762294
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.
    Orkin C; Sadiq ST; Rice L; Jackson F;
    HIV Med; 2010 Mar; 11(3):187-92. PubMed ID: 19780860
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Prevalence of human leukocyte antigen (HLA)-B*57:01 in HIV-infected patients].
    Deveci A; Çoban AY; Durupınar B
    Mikrobiyol Bul; 2016 Oct; 50(4):544-551. PubMed ID: 28124959
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
    Saag M; Balu R; Phillips E; Brachman P; Martorell C; Burman W; Stancil B; Mosteller M; Brothers C; Wannamaker P; Hughes A; Sutherland-Phillips D; Mallal S; Shaefer M;
    Clin Infect Dis; 2008 Apr; 46(7):1111-8. PubMed ID: 18444831
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.
    Rodríguez-Nóvoa S; Cuenca L; Morello J; Córdoba M; Blanco F; Jiménez-Nácher I; Soriano V
    J Antimicrob Chemother; 2010 Aug; 65(8):1567-9. PubMed ID: 20534626
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 80. HLA-B*5701 and abacavir hypersensitivity.
    Watson ME; Pimenta JM; Spreen WR; Hernandez JE
    Pharmacogenetics; 2004 Nov; 14(11):783-4; author reply 784. PubMed ID: 15564887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.